Factors that might affect risk of gadodiamide-related nephrogenic systemic fibrosis

  • Published 2007 in Nature Clinical Practice Nephrology

Abstract

membranous nephropathy, and Praga et al. have now investigated whether monotherapy with another calcineurin inhibitor—tacrolimus—has a similar effect. The trial included 48 adults with biopsy-proven membranous nephropathy, preserved renal function, nephrotic-range proteinuria (>3.5 g/24 h) and hypoalbuminemia (<3 g/dl) for ≥9 months despite treatment with… (More)
DOI: 10.1038/ncpneph0523

Topics

  • Presentations referencing similar topics